Head/Neck Cancer News

The addition of setanaxib to pembrolizumab in adults with squamous cell carcinoma of the head and neck conferred significant improvement in both PFS and OS, according to a topline data release from the agent’s manufacturer.

Researchers at Brigham and Women’s Hospital developed a tool that predicts risks for moderate to severe kidney injury after treatment with the chemotherapy drug cisplatin.

Online resources about liquid biopsies have several deficits that could prevent patients from learning about the test and better understanding , according to findings published in JAMA Network Open.

Allen S. Ho, MD, did not wait to promote active surveillance when he started practicing medicine a decade ago.

More than 20% of patients with cancer participate in some form of clinical study, and that number is considered a “floor” estimate, according to study results published in Journal of Clinical Oncology.

Adults who initiate a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those prescribed a DPP-IV inhibitor or an SGLT2 inhibitor, according to study findings published in The BMJ.

New guidelines for vaccinating adults with solid or hematologic cancers detailed the importance of vaccination optimization, multidisciplinary coordination and vaccination of household members.

Adults with low-risk papillary thyroid cancer reported low levels of decision regret for their disease management choice at 1 year, regardless of whether they chose active surveillance or surgery, according to findings published in Thyroid.

A personalized cancer vaccine produced T-cell responses in certain patients with head and neck squamous cell carcinoma, according to results from a randomized study presented at American Association for Cancer Research Annual Meeting.

Individuals with cancer reported significantly reduced pain immediately following a 10-minute virtual reality (VR) session, study results published in Cancer showed.